Group B Streptococcus Infection Treatment Market Report 2026

Group B Streptococcus Infection Treatment Market Overview

• Group B Streptococcus Infection Treatment market size has reached to $1.26 billion in 2025 • Expected to grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Rising Healthcare Expenditure Fueling The Growth Of The Market Due To Increasing Investment In Screening, Infrastructure, And Vaccine Development • Market Trend: Advancements In Simplified Vaccine Manufacturing Enhancing Immunogenicity And Reducing Bacterial Carriage • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Group B Streptococcus Infection Treatment Market?

Group B Streptococcus infection treatment refers to the medical management of infections caused by Streptococcus agalactiae, which can affect newborns, pregnant women, and adults with weakened immunity. It commonly involves antibiotic therapy to reduce bacterial load and prevent complications. Its primary purpose is to eradicate GBS bacteria, prevent complications, and reduce the risk of transmission, especially from mother to newborn. The main treatment types of Group B Streptococcus infection treatment include antibiotic therapy, intravenous immunoglobulin, and experimental therapies. Antibiotic therapy refers to the use of medications to eliminate or control bacterial infection caused by Group B Streptococcus. These treatments belong to drug classes such as beta-lactam antibiotic, clindamycin and alternatives, and pipeline therapies. The routes of administration include oral administration, intravenous administration, and topical application. The patient types include newborns, pregnant women, immunocompromised patients, and elderly population, and the end users are hospitals, clinics, research institutions, and home care settings.

What Is The Group B Streptococcus Infection Treatment Market Growth Forecast?

The group b streptococcus infection treatment market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing development of gbs vaccines, rising adoption of point-of-care diagnostics, growing focus on antimicrobial resistance management, expansion of molecular testing infrastructure, increasing emphasis on preventive maternal healthcare. Major trends in the forecast period include increasing adoption of rapid molecular diagnostic testing, rising focus on prenatal gbs screening programs, growing use of antibiotic stewardship protocols, expansion of pipeline therapies for gbs prevention, enhanced monitoring of maternal and neonatal outcomes.

Global Group B Streptococcus Infection Treatment Market Segmentation

1) By Treatment Type: Antibiotic Therapy; Intravenous Immunoglobulin (IVIG); Experimental Therapies 2) By Drug Class: Beta-Lactam Antibiotic; Clindamycin And Alternatives; Pipeline Therapies 3) By Route of Administration: Oral Administration; Intravenous Administration; Topical Application 4) By Patient Type: Newborns; Pregnant Women; Immunocompromised Patients; Elderly Population 5) By End User: Hospitals; Clinics; Research Institutions; Home Care Settings Subsegments: 1) By Antibiotic Therapy: Penicillin Based Antibiotics; Cephalosporin Antibiotics; Macrolide Antibiotics; Aminoglycoside Antibiotics 2) By Intravenous Immunoglobulin (IVIG): Standard Polyclonal Immunoglobulin; High Dose Immunoglobulin Therapy; Adjunctive Immunoglobulin Therapy 3) By Experimental Therapies: Vaccine Based Therapies; Monoclonal Antibody Therapies; Bacteriophage Therapies; Immunomodulatory Therapies

What Is The Driver Of The Group B Streptococcus Infection Treatment Market?

The rising healthcare expenditure is expected to people the growth of the group B streptococcus infection treatment market going forward. Healthcare expenditure refers to the total financial resources spent on medical services, preventive care, medications, infrastructure, and related health activities to maintain or improve population health. Healthcare expenditure is rising due to the increasing prevalence of chronic and infectious diseases, which drives sustained demand for long-term treatment, advanced therapies, and continuous medical care. Expanding healthcare expenditure strengthens group B Streptococcus infection treatment by increasing investment in prenatal screening, clinical infrastructure, and vaccine research, which together improve early detection, prevention, and effective management of GBS infections in mothers and newborns. For instance, in April 2025, according to the Office for National Statistics, a UK-based government organization, overall healthcare spending increased by 6.5% from 2023 to 2024, marking an acceleration compared with the 6.3% growth recorded in 2023. Therefore, the rising healthcare expenditure is driving the growth of the group B streptococcus infection treatment industry.

Key Players In The Global Group B Streptococcus Infection Treatment Market

Major companies operating in the group b streptococcus infection treatment market are Merck & Co. Inc., Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Biological E. Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Vaxcyte Inc., Bharat Biotech International Limited, Clover Biopharmaceuticals Ltd., Biovac Institute (Pty) Ltd., Inventprise Inc., BioNet Asia Co. Ltd., GeneOne Life Science Inc., Alopexx Enterprises LLC, Wellstat Vaccines LLC, MinervaX ApS, and ShanghAI Zerun Biotechnology Co. Ltd.

Global Group B Streptococcus Infection Treatment Market Trends and Insights

Major companies operating in the group B streptococcus infection treatment market are focusing on developing innovative products, such as polysaccharide conjugate vaccines, to reduce asymptomatic bacterial carriage. Polysaccharide conjugate vaccines are immunizations in which bacterial surface sugars are chemically linked to a carrier protein to enhance immune recognition and generate a strong, long-lasting protective response, especially in infants and young children. For instance, in September 2023, Omniose, a US-based biotechnology company, announced a grant award of up to $3.0 million from the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health to support the development of a Group B Streptococcus (GBS) vaccine. The vaccine’s unique feature lies in its aim to achieve high efficacy through a highly simplified manufacturing approach. Omniose’s platform leverages synthetic biology and a one-step enzymatic process within a single re-engineered E. coli cell to produce GBS polysaccharide conjugate vaccines, eliminating conventional chemical conjugation steps. This process preserves 100% of sialic acid residues on each capsular polysaccharide, a factor shown to be critical for inducing strong functional antibody responses against specific GBS serotypes.

What Are Latest Mergers And Acquisitions In The Group B Streptococcus Infection Treatment Market?

In September 2024, MinervaX ApS, a Denmark-based biotechnology company developing a novel prophylactic vaccine against Group B Streptococcus (GBS), partnered with Wacker Biotech B.V. to scale up the manufacturing of active protein ingredients for MinervaX’s GBS vaccine. Through this collaboration, MinervaX and Wacker Biotech aim to ensure robust late-stage clinical and commercial supply, enabling maternal vaccination to prevent adverse pregnancy outcomes and life-threatening infections in infants, as well as vaccination of older or at-risk adults. Wacker Biotech B.V. is a Germany-based company specializing in E. coli processes, technology transfer, process validation, and process characterization to support stable, high-quality vaccine production for global patient populations.

Regional Insights

North America was the largest region in the group B streptococcus infection treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Group B Streptococcus Infection Treatment Market?

The group B streptococcus infection treatment market consists of revenues earned by entities by providing services such as prenatal screening and diagnostic testing, microbiological culture and molecular testing, clinical consultations for infection management, and antibiotic administration and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The group B streptococcus infection treatment market also includes sales of intrapartum prophylactic formulations, rapid diagnostic kits, molecular testing assays, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Group B Streptococcus Infection Treatment Market Report 2026?

The group b streptococcus infection treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the group b streptococcus infection treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.